South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...

Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

Ulcerative colitis (UC) is one of the two major types of chronic inflammatory bowel diseases (IBD), along with Crohn’s disease. UC affects the large bowel, has no known cure, and requires lifelong ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Korean pharmaceutical giant Celltrion on Tuesday pledged to achieve an annual growth rate of 30 percent and a return on equity of at least 7 percent by 2027, as part of its long-term initiative aimed ...

Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in s ...

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of ...